For example, FGF401, a selective FGF19‐FGFR4 signaling inhibitor, has shown favorable safety profiles and preliminary clinical efficacy in FGFR4/KLB‐positive HCC patients. This evidence concerns the gene FGFR4 and hepatocellular carcinoma.